Table 1.
Clinical Characteristics of 60 Patients With COVID-19 Pneumonia
| Characteristic | Patients | Normal Range |
|---|---|---|
| Age, y, median (IQR) | 60 (38–66) | … |
| Male, No. (%) | 22 (37) | … |
| Comorbidities, No. (%) | ||
| Hypertension | 9 (15) | … |
| Diabetes | 6 (10) | … |
| Heart diseases | 1 (2) | … |
| Symptoms, No. (%) | ||
| Fever | 42 (70) | … |
| Cough | 29 (48) | … |
| Breath shortness | 19 (32) | … |
| Myalgia | 8 (13) | … |
| Bilateral lung distribution, No. (%) | 40 (67) | … |
| Severe illness on admission, No. (%) | 19 (32) | … |
| Blood count, ×109/L, median (IQR) | ||
| Leukocyte | 4.2 (3.3–5.9) | 3.5–9.5 |
| Neutrophil | 2.8 (2.2–4.5) | 1.8–6.3 |
| Lymphocyte | 0.8 (0.6–1.2) | 1.1–3.2 |
| Platelet | 186 (131–225) | 125–350 |
| Inflammatory indicators, median (IQR) | ||
| ESR, mm/h | 24 (11–41) | 0–15 |
| C-reactive protein, mg/L | 26 (9–67) | 0–10 |
| Interleukin-6, pg/mL | 13 (6–29) | 0–7 |
| Treatment, No. (%) | ||
| Oxygen inhalation | 28 (47) | … |
| Corticosteroid | 27 (45) | … |
| Antiviral treatment | 41 (68) | … |
| Arbidol | 22 (37) | … |
| Darunavir and cobicistat | 14 (23) | … |
| Lopinavir and ritonavir | 10 (17) | … |
| Remdesivir | 9 (15) | … |
| Ribavirin | 6 (10) | … |
| Interferon inhalation | 19 (32) | … |
| Immune enhancer | 23 (38) | … |
| Thymalfasin | 19 (32) | … |
| Immunoglobulin | 6 (10) | … |
Abbreviations: COVID-19, coronavirus disease 2019; ESR, erythrocyte sedimentation rate; IQR, interquartile range.